Notice

Held in Songdo, Incheon for 2 days starting June 29th

Participating with partner companies such as Ajinomoto Genexine and Natural Science-Hamilton Group

Ajinomoto Genexine, a cell culture medium research and manufacturing company, will participate in ‘Biologics Manufacturing 

Korea 2022 (BMK 2022)’, which will be held at Songdo Convensia in Incheon for two days from June 29.

The BMK Conference, now in its 11th year, is an event hosted by IMAPAC, a social enterprise located in Singapore. It is held every year in Korea as a networking venue where governments, NGOs, biopharmaceutical companies, and academic experts from each country gather to share know-how in manufacturing and developing high-quality biopharmaceuticals and vaccines.

In this BMK 2022, more than 550 organizations and biopharmaceutical industry representative entrepreneurs from home and 

abroad will participate. There will be heated discussions between experts on topics such as ‘Korea’s biopharmaceutical success 

stories’, ‘international biopharmaceuticals and large pharmaceutical companies’ technological expertise’, and ‘presentations on the latest manufacturing technology and industry innovation strategies’. Additionally, about 50 experts will appear as speakers and 

share the latest knowledge. A time was also provided for vaccine manufacturers, research institutes, and officials from related 

organizations to have face-to-face networking.

Ajinomoto Genexine will participate in this conference together with Natural Science Co., Ltd., which supplies basic laboratory 

equipment and cutting-edge equipment in the life science field, and Hamilton Group, which has incubator sensor technology. 

We plan to promote cell culture medium technology based on the ‘CELLiST (CELiST)’ series developed based on Ajinomoto’s 

medium manufacturing technology and know-how.

An official from Ajinomoto Genexine said, “Ajinomoto Genecine has proposed a method that can improve the productivity of the domestic bio industry as well as improve antibody quality and reduce costs through the cell culture media change (Media Switch) program,” and added, “Ajinomoto Genec at this BMK 2022 as well. “We expect there will be many visits and interest from 

domestic and foreign bio industry figures who are interested in Shin and CELLiST,” he said.